CellSource Co., Ltd. (4880.T)
JPY 636.0
(2.75%)
JPY 636.0
(2.75%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.22 Billion JPY | -22.25% |
| 2022 | 1.57 Billion JPY | 58.3% |
| 2021 | 992.44 Million JPY | 138.83% |
| 2020 | 415.55 Million JPY | 27.1% |
| 2019 | 326.94 Million JPY | 10.79% |
| 2018 | 295.09 Million JPY | 85.41% |
| 2017 | 159.15 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 75.61 Million JPY | -63.27% |
| 2024 Q1 | 205.86 Million JPY | 15.47% |
| 2024 Q3 | 106.65 Million JPY | 41.05% |
| 2023 Q3 | 383.87 Million JPY | 24.61% |
| 2023 FY | 1.22 Billion JPY | -22.25% |
| 2023 Q4 | 178.28 Million JPY | -53.56% |
| 2023 Q2 | 308.05 Million JPY | -12.31% |
| 2023 Q1 | 351.28 Million JPY | -44.44% |
| 2022 Q4 | 632.28 Million JPY | 41.13% |
| 2022 FY | 1.57 Billion JPY | 58.3% |
| 2022 Q2 | 246.37 Million JPY | 0.82% |
| 2022 Q1 | 244.37 Million JPY | -22.11% |
| 2022 Q3 | 448.01 Million JPY | 81.84% |
| 2021 Q2 | 242.25 Million JPY | 34.42% |
| 2021 Q1 | 180.22 Million JPY | 10.73% |
| 2021 Q3 | 256.23 Million JPY | 5.77% |
| 2021 Q4 | 313.73 Million JPY | 22.44% |
| 2021 FY | 992.44 Million JPY | 138.83% |
| 2020 Q4 | 162.76 Million JPY | 150.62% |
| 2020 Q2 | 63.22 Million JPY | -49.27% |
| 2020 Q1 | 124.62 Million JPY | 25.83% |
| 2020 FY | 415.55 Million JPY | 27.1% |
| 2020 Q3 | 64.94 Million JPY | 2.72% |
| 2019 FY | 326.94 Million JPY | 10.79% |
| 2019 Q4 | 99.04 Million JPY | 0.0% |
| 2018 FY | 295.09 Million JPY | 85.41% |
| 2017 FY | 159.15 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | -104.667% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | 345.84% |
| GNI Group Ltd. | 13.1 Billion JPY | 90.682% |
| Linical Co., Ltd. | 725.72 Million JPY | -68.315% |
| Trans Genic Inc. | 89.43 Million JPY | -1265.78% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 185.662% |
| Soiken Holdings Inc. | -610 Million JPY | 300.243% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | 258.073% |
| AnGes, Inc. | -11.96 Billion JPY | 110.207% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 208.985% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 112.823% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | -1071.151% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | 241.309% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 209.357% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 196.791% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | 252.963% |
| RaQualia Pharma Inc. | -337.36 Million JPY | 462.07% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 201.355% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 191.457% |
| PeptiDream Inc. | 6.77 Billion JPY | 81.965% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 163.291% |
| Ribomic Inc. | -1.11 Billion JPY | 209.434% |
| SanBio Company Limited | -4.53 Billion JPY | 126.911% |
| Healios K.K. | -3.37 Billion JPY | 136.15% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 205.75% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 187.656% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 187.063% |
| StemRIM | -2.07 Billion JPY | 158.839% |
| FunPep Company Limited | -994 Million JPY | 222.887% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 237.438% |
| Stella Pharma Corporation | -760.3 Million JPY | 260.66% |
| TMS Co., Ltd. | -943.25 Million JPY | 229.499% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 257.533% |
| Cuorips Inc. | -588.48 Million JPY | 307.566% |
| K Pharma,Inc. | 366.05 Million JPY | -233.691% |
| Takara Bio Inc. | 3 Billion JPY | 59.324% |
| ReproCELL Incorporated | -409.29 Million JPY | 398.441% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | -10941.3% |
| StemCell Institute Inc. | 413.75 Million JPY | -195.22% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | -745.287% |
| CellSeed Inc. | -697.77 Million JPY | 275.056% |